KR102712005B1 - 신규 니코틴-결합 항체 - Google Patents

신규 니코틴-결합 항체 Download PDF

Info

Publication number
KR102712005B1
KR102712005B1 KR1020207007504A KR20207007504A KR102712005B1 KR 102712005 B1 KR102712005 B1 KR 102712005B1 KR 1020207007504 A KR1020207007504 A KR 1020207007504A KR 20207007504 A KR20207007504 A KR 20207007504A KR 102712005 B1 KR102712005 B1 KR 102712005B1
Authority
KR
South Korea
Prior art keywords
ser
val
thr
leu
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207007504A
Other languages
English (en)
Korean (ko)
Other versions
KR20200089255A (ko
Inventor
매튜 더블유. 칼닉
주자나 비소바
토마스 디스테드
스티브 풀러
마그 쥐 르사주
니콜라 벨트라마넬리
스테파니 팔루
폴 펜텔
Original Assignee
블링크 바이오메디컬 에스아에스
앤티도트 테라퓨틱스 인코퍼레이티드
헤네핀 헬스케어 리서치 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 블링크 바이오메디컬 에스아에스, 앤티도트 테라퓨틱스 인코퍼레이티드, 헤네핀 헬스케어 리서치 인스티튜트 filed Critical 블링크 바이오메디컬 에스아에스
Publication of KR20200089255A publication Critical patent/KR20200089255A/ko
Application granted granted Critical
Publication of KR102712005B1 publication Critical patent/KR102712005B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020207007504A 2017-08-15 2018-08-14 신규 니코틴-결합 항체 Active KR102712005B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545696P 2017-08-15 2017-08-15
US62/545,696 2017-08-15
PCT/US2018/046621 WO2019036419A1 (en) 2017-08-15 2018-08-14 NEW NICOTINE BINDING ANTIBODIES

Publications (2)

Publication Number Publication Date
KR20200089255A KR20200089255A (ko) 2020-07-24
KR102712005B1 true KR102712005B1 (ko) 2024-09-30

Family

ID=63405495

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207007504A Active KR102712005B1 (ko) 2017-08-15 2018-08-14 신규 니코틴-결합 항체

Country Status (11)

Country Link
US (2) US11440970B2 (enExample)
EP (2) EP4624496A3 (enExample)
JP (1) JP7364555B2 (enExample)
KR (1) KR102712005B1 (enExample)
CN (1) CN111432883B (enExample)
AU (1) AU2018317372B2 (enExample)
BR (1) BR112020002994A2 (enExample)
CA (1) CA3072767A1 (enExample)
ES (1) ES3041362T3 (enExample)
MX (1) MX2020001725A (enExample)
WO (1) WO2019036419A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112512549A (zh) * 2018-06-06 2021-03-16 安蒂多特疗法公司 改善循环和治疗心血管疾病的方法
KR102530111B1 (ko) * 2022-03-11 2023-05-10 앱클론(주) 코티닌을 표적하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이들의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194158A3 (en) * 1985-03-08 1988-02-24 Baylor College of Medicine Anti-nicotine and anti-cotinine antibodies (monoclonal and other), and their uses in nicotine and cotinine assays
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002251821A1 (en) 2001-01-26 2002-08-06 The Scripps Research Institute Nicotine immunogens and antibodies and uses thereof
WO2003082329A2 (en) 2002-03-01 2003-10-09 The Board Of Regents Of The University Of Nebraska Compositions and compounds for use as molecular adjuvant for a nicotine vaccine
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US20060111271A1 (en) 2004-11-24 2006-05-25 Cerny Erich H Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements
US8316104B2 (en) * 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
EP1963308A4 (en) 2005-11-28 2010-12-15 Nabi Biopharmaceuticals METHOD FOR PRODUCING A NICOTINE HAPTEN
WO2007100755A1 (en) 2006-02-27 2007-09-07 Nabi Biopharmaceuticals Method for decreasing the toxic effects of nicotine on fetuses in pregnant women
EP2222702B1 (en) * 2007-11-29 2016-01-13 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
EP2065398A1 (en) 2007-11-29 2009-06-03 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
MX2010013583A (es) 2008-06-13 2011-05-19 Nabi Biopharmaceuticals Kit y metodo para dejar de fumar.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Drug metabolism and Disposition (2005) vol. 33, No. 7, pp. 1056-1061(2005.07.01). 1부*
J Biol Chem. 2015 Feb 27, 290(9) 5462-5469(2015.02.27.) 1부*
The Journal of Pharmacology and Experimental Therapeutics (2006) vol. 317, No. 2, pp. 660-666(2006.05.01.) 1부*

Also Published As

Publication number Publication date
US11440970B2 (en) 2022-09-13
AU2018317372B2 (en) 2025-06-26
CN111432883B (zh) 2024-10-01
MX2020001725A (es) 2020-08-20
EP3668598B1 (en) 2025-07-30
KR20200089255A (ko) 2020-07-24
US20200377616A1 (en) 2020-12-03
AU2018317372A1 (en) 2020-03-05
WO2019036419A1 (en) 2019-02-21
EP4624496A2 (en) 2025-10-01
JP2020531480A (ja) 2020-11-05
EP4624496A3 (en) 2025-12-17
JP7364555B2 (ja) 2023-10-18
CA3072767A1 (en) 2019-02-21
CN111432883A (zh) 2020-07-17
ES3041362T3 (en) 2025-11-11
US20230089068A1 (en) 2023-03-23
BR112020002994A2 (pt) 2020-08-11
EP3668598A1 (en) 2020-06-24

Similar Documents

Publication Publication Date Title
Kosten et al. Immunotherapy for the treatment of drug abuse
TWI697334B (zh) 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
De Villiers et al. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell
AU2007238677B2 (en) Use of IL-I antibodies for treating ophthalmic disorders
Treweek et al. An antidote for acute cocaine toxicity
RS65360B1 (sr) Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
LeSage et al. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies
RS59354B1 (sr) Postupci lečenja nosne polipoze davanjem il-4r antagonista
US20230089068A1 (en) Novel nicotine-binding antibodies
CN115698059A (zh) 使用抗bet v 1抗体治疗过敏的方法
CN112639087A (zh) 新型尼古丁降解酶变体
TW202126699A (zh) 用於抗類胰蛋白酶抗體之投藥
US20220267474A1 (en) Methods for improving circulation and treating cardiovascular disease
Pashmi Immunotherapy approach to combat nicotine addiction
EA049619B1 (ru) Способы лечения аллергии с применением антител к bet v 1
ES2864350T3 (es) Pautas posológicas para uso con inhibidores de PCSK9
Pentel Hennepin County Medical Center and University of Minnesota
Coy A nicotine conjugate vaccine attenuates the behavioral and cardiovascular effects of nicotine in rats
Rice Effects of nicotine vaccination on blood pressure and grip strength
Oliver Vaccination against cotinine as a potential approach to smoking cessation
HK40008538A (en) Treating refractory migraine
BR122024004106A2 (pt) Uso de um anticorpo que se liga a uma calicreína plasmática ativa (pkal) e não se liga à precalicreína humana no tratamento de doenças da retina

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200313

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210817

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230818

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240520

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230818

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20240820

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20240826

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240925

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240926

End annual number: 3

Start annual number: 1

PG1601 Publication of registration